超声引导葡萄糖注射治疗慢性肌筋膜疼痛综合征：回顾性病例系列研究。
Ultrasound-guided dextrose injection treatment for chronic myofascial pain syndrome: A retrospective case series.
机构信息
Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC.
出版信息
J Chin Med Assoc. 2020 Sep;83(9):876-879. doi: 10.1097/JCMA.0000000000000339.
BACKGROUND
Due to the lack of an evidence-based consensus, managing refractory myofascial pain syndrome is challenging for clinicians. Dextrose injection (dextrose prolotherapy) emerged as a promising, cost-effective treatment. This study evaluated the efficacy of targeted ultrasound-guided dextrose injection for localized myofascial pain syndrome.
METHODS
We retrospectively reviewed the clinical outcomes of 45 patients with myofascial pain syndrome refractory to alternative treatments with targeted ultrasound-guided dextrose injection. Pretreatment symptom severity and symptomatic response 1 month after treatment were statistically analyzed using a visual analog scale (VAS)-based scoring system.
RESULTS
Of 45 patients, 8 (24.4%) reported complete resolution of symptoms at the treated site. In total, 36 (80.0%) patients reported greater than 50% improvement in their symptoms. The mean pretreatment and posttreatment VAS scores were 7.0 and 2.44 (p < 0.001), indicating an overall 65.0% reduction in symptom severity.
CONCLUSION
Targeted ultrasound-guided dextrose injection was remarkably effective for refractory localized myofascial pain syndrome, significantly reducing symptom intensities in the majority of treated patients within 1 month after a single injection.
背景
由于缺乏基于证据的共识，管理难治性肌筋膜疼痛综合征对临床医生来说具有挑战性。葡萄糖注射（葡萄糖增生疗法）作为一种有前途且具有成本效益的治疗方法出现了。本研究评估了靶向超声引导葡萄糖注射治疗局部肌筋膜疼痛综合征的疗效。
方法
我们回顾性分析了 45 例接受靶向超声引导葡萄糖注射治疗的难治性肌筋膜疼痛综合征患者的临床结果。使用基于视觉模拟量表（VAS）的评分系统对治疗前的症状严重程度和治疗后 1 个月的症状反应进行统计学分析。
结果
在 45 例患者中，8 例（24.4%）在治疗部位的症状完全缓解。总共有 36 例（80.0%）患者报告症状改善超过 50%。治疗前和治疗后的 VAS 评分平均值分别为 7.0 和 2.44（p < 0.001），表明症状严重程度总体降低了 65.0%。
结论
靶向超声引导葡萄糖注射对难治性局部肌筋膜疼痛综合征非常有效，在单次注射后 1 个月内，大多数接受治疗的患者的症状强度显著降低。
Zotero 插件